Correlation of serum level of HER-2 extracellular domain with HER-2 expression in tumor tissue of breast cancer patients and clinical significance

doi:10.3877/cma.j.issn.1674-0807.2016.01.004

Abstract

Abstract:

Objective

To investigate the correlation between serum level of HER-2 extracellular domain (ECD) and HER-2 expression in tumor tissue of breast cancer patients and their relationship with clinicopathological parameters respectively.

Methods

Totally 93 breast cancer patients in Chongqing Cancer Institute from August 2013 to January 2014 were enrolled in this retrospective study. Those patients' serum and fresh tumor tissue samples were collected. Serum HER-2 ECD levels were measured by chemiluminescence immunoassay. HER-2 expression in tumor tissue was assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The results of serum HER-2 ECD levels and HER-2 expression in tumor tissue were compared,and their correlation with clinicopathological parameters was analyzed using χ² test or Fisher's exact probability test. t test was used to compare serum HER-2 ECD levels between HER-2 positive group and HER-2 negative group. The consistency of HER-2 level detected by serological method and histological method was analyzed by Kappa test. The correlation between tumor TNM staging and serum HER-2 ECD level was analyzed by Spearman rank test.

Results

There were 30 patients with HER-2 positive expression and 63 with HER-2 negative in 93 breast cancer patients. The serum HER-2 ECD level in HER-2 positive group was (22.18±22.38) ng/ml, significantly higher than (10.19±2.01) ng/ml in HER-2 negative group (t=-4.209, P＜0.001). As for HER-2 detection, serological method showed a good consistency with histological method (Kappa=0.519, P＜0.001). The serum HER-2 ECD level in breast cancer patients was correlated with distal metastasis (P=0.013), tumor TNM staging (r=0.213,P=0.042), ER and PR status(χ²=6.206,11.853;P=0.013, 0.001), but not related to the patient's age (χ² =0.607,P=0.436),tumor size (P=0.109), regional lymph node status (P=0.106), Ki67 and p53 expression (χ² =0.349,0.076;P= 0.555, 0.782). The positive rate of HER-2 in tumor tissue in ER/PR negative patients was significantly higher than that in ER/PR positive patients (χ² = 15.368, 24.733; all P ＜0.001).

Conclusions

There is a significant correlation between serum HER-2 ECD level and HER-2 status in tumor tissue. The detection of serum HER-2 ECD level could be used as a supplement of histological detection to monitor continuous dynamic changes of HER-2 and provide objective references for clinical management of breast cancer.

Key words: Breast neoplasms, Receptor, epidermal growth factor, Chemiluminescent measurements, Immunoassay

Yongpeng He, Lixian Li, Lin Yi, Chuang Ge, Weiqi Nian, Xiaodong Zheng. Correlation of serum level of HER-2 extracellular domain with HER-2 expression in tumor tissue of breast cancer patients and clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(01): 14-19.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2016.01.004

https://zhrxbzz.cma-cmc.com.cn/EN/Y2016/V10/I01/14

Figures/Tables 2

References 28

[1]	Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods [ J]. JAMA, 2004,291(16):1972-1977.
[2]	Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study[J]. J Clin Oncol,2010,28(12):2024-2031.
[3]	Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial [J]. Lancet,2007,369(9555):29-36.
[4]	Fergenbaum JH, Garcia-Closas M, Hewitt SM, et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays[J].Cancer Epidemiol Biomarkers Prev,2004,13(4):667-672.
[5]	Pupa SM, Ménard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage[J]. Oncogene,1993,8(11):2917-2923.
[6]	Lee SB,Lee JW,Yu JH,et al. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer[J]. BMC Cancer,2014,14:929.
[7]	Kong Y, Dai S, Xie X, et al. High serum HER2 extracellular domain levels:correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients[J]. J Cancer Res Clin Oncol,2012,138(2):275-284.
[8]	Farzadnia M, Meibodi NT, Shandiz FH, et al. Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters[J]. Breast,2010,19(6):489-492.
[9]	廖天,陆云飞. 乳腺癌患者血清HER2/neu 水平与其组织HER2 表达状态的关系[J]. 广西医科大学学报,2009,26(6):859-861.
[10]	Edge S, Byrd DR, Compton CC. AJCC cancer staging manual [M].7th ed. New York: Springer,2010:345-376.
[11]	Lüftner D, Cheli C, Mickelson K, et al. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer[J]. Int J Biol Markers,2004,19(3):175-182.
[12]	Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/college of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014,138(2):241-256.
[13]	Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)[J]. Arch Pathol Lab Med,2010,134(7): e48-72.
[14]	Dowsett M, Nielsen TO, A'hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group[J]. J Natl Cancer Inst, 2011, 103(22):1656-1664.
[15]	王永南, 王颀, 张安秦,等. ER、PR、HER2 和Ki-67 在乳腺癌新辅助化疗前后表达变化的临床意义[J]. 岭南现代临床外科, 2013,13(4):308-312.
[16]	Kobayashi T, Iwaya K, Moriya T, et al. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer[J].BMC Clin Pathol,2013,13:5.
[17]	Alroy I, Yarden Y. Biochemistry of HER2 oncogenesis in breast cancer[J]. Breast Dis,2000,11:31-48.
[18]	Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? [J]. Breast Cancer Res,2001,3(5):304-312.
[19]	Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls[J]. Lancet Oncol,2011,12(3):286-295.
[20]	Ryu DW, Lee CH. Impact of serum HER2 levels on survival and its correlation with clinicopathological parameters in women with breast cancer[J]. J Breast Cancer,2012,15(1):71-78.
[21]	Di Gioia D, Dresse M, Mayr D, et al. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer[J]. Clin Chim Acta,2015,440:16-22.
[22]	Sorensen PD, Jakobsen EH, Madsen JS, et al. Serum HER-2:sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients[J]. J Cancer Res Clin Oncol,2013,139(6):1005-1013.
[23]	Sorensen PD, Jakobsen EH, Langkjer ST, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting[J]. Clin Chem Lab Med,2009,47(9):1117-1123.
[24]	Kuroda N, Kontani K, Kajikawa T, et al. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method[J]. Rinsho Byori,2010,58(6):541-552.
[25]	Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD[J]. Biochim Biophys Acta, 2012,1826(1):199-208.
[26]	Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer[J]. N Engl J Med, 2008, 358(13):1409-1411.
[27]	Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status[J]. Breast Cancer Res, 2007,9(5): R74.
[28]	Ha JH, Seong MK, Kim EK, et al. Serial serum HER2 measurements for the detection of breast cancer recurrence in HER2-positive patients[J]. J Breast Cancer,2014,17(1):33-39.

血清HER-2 ECD	癌组织HER-2		合计
血清HER-2 ECD	阳性	阴性	合计
阳性	14(93.3)	1(6.7)	15(100.0)
阴性	16(20.5)	62(79.5)	78(100.0)
合计	30(32.3)	63(67.7)	93(100.0)

血清HER-2 ECD	癌组织HER-2		合计
血清HER-2 ECD	阳性	阴性	合计
阳性	14(93.3)	1(6.7)	15(100.0)
阴性	16(20.5)	62(79.5)	78(100.0)
合计	30(32.3)	63(67.7)	93(100.0)

Please choose a citation manager

Content to export